BioVie Inc. Secures Funding Through Direct Offering and Placement
Announcing a pivotal moment for the company, BioVie Inc. (NASDAQ: BIVI) is making strides in the pharmaceutical landscape with its recently priced registered direct offering. This innovative clinical-stage firm focuses on developing transformative therapies targeting chronic debilitating conditions, notably liver disease and neurological disorders.
Details of the Offering
In this latest offering, BioVie plans to sell approximately 4,443,000 shares of its common stock, priced at $1.50 per share, aiming for an impressive total gross result of $6,664,500 before considering placement agent fees and various related expenses. This capital will be a significant boost for the company as it navigates its ongoing projects.
Warrants and Their Significance
As part of the financing structure, the company will also issue unregistered warrants to investors, providing an opportunity to purchase an equivalent number of common stock shares at a slightly lower price of $1.37 each. These warrants are designed to become exercisable six months post-issuance and will remain valid for five years, adding additional value for shareholders.
Utilization of Proceeds
BioVie intends to allocate the net proceeds primarily toward working capital and general corporate needs, reinforcing its operational foundation. The shares and associated warrants from this direct offering will significantly bolster the company’s financial flexibility as it advances its unique drug therapies.
Expected Closure Timeline
The offering and private placement are projected to close shortly, pending standard contractual conditions. With ThinkEquity serving as the sole placement agent, the transaction is poised to enrich BioVie’s capital resources considerably.
About BioVie Inc.
Delving deeper into the company’s mission, BioVie Inc. is dedicated to pioneering innovative drug therapies, particularly targeting neurological and neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases, along with advanced liver diseases. Their leading candidate, bezisterim, shows promise in curbing neuroinflammation and addressing insulin resistance—key factors in numerous neurodegenerative disorders.
The Fight Against Liver Disease
In parallel, BioVie is developing BIV201, a continuous infusion of terlipressin designated as an Orphan drug. This candidate is currently under FDA Fast Track status and is undergoing discussions to shape its Phase 3 clinical trial designs, primarily aimed at easing complications arising from liver cirrhosis and ascites. The active agent has already gained approval in the U.S. and around 40 other nations for similar advanced liver issues.
Inquiries and Contact
For those interested in learning more, BioVie Inc. encourages reaching out to their dedicated investor relations personnel. Bruce Mackle, the Managing Director at LifeSci Advisors, LLC, is available for inquiries via email.
Media inquiries should be directed to Melyssa Weible, Managing Partner at Elixir Health Public Relations, ensuring clear communication and access to relevant information.
Frequently Asked Questions
What is the purpose of the direct offering by BioVie Inc.?
The direct offering aims to generate capital to support the company's working capital and general corporate purposes.
What details were disclosed about the warrants in the offering?
Investors will receive unregistered warrants to purchase shares at an exercise price of $1.37, exercisable starting six months from issuance.
How much capital is BioVie seeking through this offering?
BioVie is looking to raise approximately $6,664,500 through the registered direct offering priced at $1.50 per share.
What stage is BioVie in regarding their drug development?
BioVie is a clinical-stage company focused on developing innovative therapies for chronic conditions, particularly neurodegenerative disorders and liver disease.
Who is the placement agent for the offering?
ThinkEquity is acting as the sole placement agent for BioVie’s direct offering and private placement.
